Table 1 Prognostic analysis of APOL isoforms for patient survival in GSE14520 cohort.

Type	Variables	Patients	Patients survival
Type	Variables	(n = 212)	No. of event	MST (month)	HR (95%CI)	Crude P value	HR (95%CI)	Adjusted P value^ɸ
OS	APOL1					0.025		0.125
	Low expression	106	48	60.5	Reference		Reference
	High expression	106	34	NA	0.605 (0.390–0.940)		0.700 (0.444–1.104)
	APOL2					0.075		0.164
	Low expression	106	46	NA	Reference		Reference
	High expression	106	36	NA	0.672 (0.434–1.040)		0.729 (0.467–1.137)
	APOL3					0.013		0.032
	Low expression	106	49	60.5	Reference		Reference
	High expression	106	33	NA	0.571 (0.367–0.888)		0.610 (0.387–0.959)
	APOL5					0.394		0.242
	Low expression	106	44	NA	Reference		Reference
	High expression	106	38	NA	0.828 (0.536–1.278)		0.764 (0.487–1.199)
	APOL6					< 0.001		0.007
	Low expression	106	53	54.8	Reference		Reference
	High expression	106	29	NA	0.434 (0.276–0.684)		0.527 (0.331–0.840)
RFS	APOL1					0.069		0.145
	Low expression	106	62	28.2	Reference		Reference
	High expression	106	54	53.0	0.713 (0.495–1.027)		0.757 (0.520–1.101)
	APOL2					0.016		0.023
	Low expression	106	66	29.9	Reference		Reference
	High expression	106	50	57.9	0.635 (0.439–0.917)		0.648 (0.446–0.942)
	APOL3					0.007		0.018
	Low expression	106	66	26.9	Reference		Reference
	High expression	106	50	57.9	0.601 (0.416–0.869)		0.634 (0.435–0.924)
	APOL5					0.731		0.641
	Low expression	106	59	40.1	Reference		Reference
	High expression	106	57	51.1	0.938 (0.652–1.351)		0.916 (0.633–1.326)
	APOL6					0.001		0.004
	Low expression	106	68	23.0	Reference		Reference
	High expression	106	48	59.5	0.519 (0.358–0.751)		0.571 (0.392–0.833)

ɸ: P values were adjusted for tumor size, cirrhosis, AFP and BCLC stage in OS and were adjusted for gender, cirrhosis and BCLC stage in RFS; Bold indicates significant P values.
NA: not available; MST: median survival time; HR: hazard ratio; 95%CI: 95% confidence interval; OS: overall survival; RFS: recurrence-free survival.

Search